Minerva Neurosciences | NERV - Selling And Administration Expenses


Minerva Neurosciences reported $2.48M in Selling and Administration Expenses for its fiscal quarter ending in September of 2024.





Selling And Administration Expenses Change Date
Acadia Pharmaceuticals USD 146.73M 21.82M Dec/2025
Adma Biologics USD 23.05M 320K Sep/2025
ALKERMES USD 187.2M 15.43M Dec/2025
Alterity Therapeutics Limited AUD 2.29M 649.1K Jun/2023
AstraZeneca USD 4.61B 4.46B Dec/2025
BioCryst Pharmaceuticals USD 80.47M 15.39M Dec/2024
Bristol-Myers Squibb USD 2.18B 392M Dec/2025
Cipla INR 13.25B 101.8M Dec/2025
Clal Biotechnology ILS 3.31M 513K Dec/2022
Compugen USD 2.33M 50K Sep/2025
CSL USD 1.23B 498M Dec/2025
Eli Lilly USD 3.13B 391.3M Dec/2025
Esperion Therapeutics USD 39.98M 4.21M Sep/2024
GlaxoSmithKline GBP 2.68B 518M Dec/2025
Grifols EUR 333.1M 157M Sep/2025
Halozyme Therapeutics USD 64.64M 27.11M Dec/2025
Ionis Pharmaceuticals USD 130M 43.43M Dec/2025
J&J USD 6.75B 831M Dec/2025
Merck USD 2.85B 215M Dec/2025
Minerva Neurosciences USD 2.48M 58.79K Sep/2024
Neurocrine Biosciences USD 301.8M 10.2M Dec/2025
Novartis USD 3.31B 134M Sep/2025
Novavax USD 66.95M 34.05M Sep/2024
Pfizer USD 4.08B 894M Dec/2025
Roche Holding CHF 7.28B 3.99B Dec/2025
Sanofi EUR 2.75B 455M Dec/2025
Takeda JPY 282.78B 29.23B Dec/2025
Vanda Pharmaceuticals USD 39.28M 1.71M Dec/2024